Article
Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice.
Oncogene - 11 Jun 2009
Goel V K, Ibrahim N, Jiang G, Singhal M, Fee S, Flotte T, Westmoreland S, Haluska F S, Hinds P W, Haluska F G
Abstract excerpt
BRAF, a cellular oncogene and effector of RAS-mediated signaling, is activated by mutation in approximately 60% of melanomas. Most of these mutations consist of a V600E substitution resulting in constitutive kinase activation. Mutant BRAF thus represents an important therapeutic target in melanoma. In an effort to produce a pre-clinical model of mutant BRAF function in melanoma, we have generated a mouse...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.